Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Expert Opinion on Biological Therapy
|
March 1, 2006
In vivo behaviour of antibody-drug conjugates for the targeted treatment of cancer
Hongsheng Xie, Walter A Blättler
Protein Science : a Publication of the Protein Society
|
August 6, 2005
Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry
Lintao Wang, Godfrey Amphlett, Walter A Blättler, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
November 25, 2003
Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice
Hongsheng Xie, Charlene Audette, Mary Hoffee, et al.
Chemical Society Reviews
|
February 22, 2012
Developing drug molecules for therapy with carbon monoxide
Carlos C Romão, Walter A Blättler, João D Seixas, et al.
Rapid Communications in Mass Spectrometry : RCM
|
June 10, 2005
Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry
Alexandru C Lazar, Lintao Wang, Walter A Blättler, et al.
Cancer Research
|
August 28, 2003
An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation
Erin K Maloney, Jennifer L McLaughlin, Nancy E Dagdigian, et al.
Cancer Research
|
April 19, 2006
Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing
Hans K Erickson, Peter U Park, Wayne C Widdison, et al.
Cancer Research
|
March 17, 2006
Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen
Yelena V Kovtun, Charlene A Audette, Yumei Ye, et al.
Journal of Medicinal Chemistry
|
July 11, 2006
Semisynthetic maytansine analogues for the targeted treatment of cancer
Wayne C Widdison, Sharon D Wilhelm, Emily E Cavanagh, et al.
Cancer Research
|
November 18, 2008
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate
Gail D Lewis Phillips, Guangmin Li, Debra L Dugger, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Expert Opinion on Biological Therapy
|
March 1, 2006
In vivo behaviour of antibody-drug conjugates for the targeted treatment of cancer
Hongsheng Xie, Walter A Blättler
Protein Science : a Publication of the Protein Society
|
August 6, 2005
Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry
Lintao Wang, Godfrey Amphlett, Walter A Blättler, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
November 25, 2003
Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice
Hongsheng Xie, Charlene Audette, Mary Hoffee, et al.
Chemical Society Reviews
|
February 22, 2012
Developing drug molecules for therapy with carbon monoxide
Carlos C Romão, Walter A Blättler, João D Seixas, et al.
Rapid Communications in Mass Spectrometry : RCM
|
June 10, 2005
Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry
Alexandru C Lazar, Lintao Wang, Walter A Blättler, et al.
Cancer Research
|
August 28, 2003
An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation
Erin K Maloney, Jennifer L McLaughlin, Nancy E Dagdigian, et al.
Cancer Research
|
April 19, 2006
Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing
Hans K Erickson, Peter U Park, Wayne C Widdison, et al.
Cancer Research
|
March 17, 2006
Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen
Yelena V Kovtun, Charlene A Audette, Yumei Ye, et al.
Journal of Medicinal Chemistry
|
July 11, 2006
Semisynthetic maytansine analogues for the targeted treatment of cancer
Wayne C Widdison, Sharon D Wilhelm, Emily E Cavanagh, et al.
Cancer Research
|
November 18, 2008
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate
Gail D Lewis Phillips, Guangmin Li, Debra L Dugger, et al.
Page
of 1